Cailin Harris represents public and private company clients in a broad range of corporate and transactional matters, including mergers and acquisitions, debt and equity financings, and securities law compliance. Cailin has experience in assisting with the drafting and negotiation of transactional documents in connection with asset sales and acquisitions, stock sales and acquisitions, private and public mergers, and private equity portfolio acquisitions. She also advises clients on corporate governance, commercial contracts, SEC disclosure and reporting under the ’34 Act and in ’33 Act registration statements, annual meeting and proxy-related matters and matters relating to compliance with the rules and regulations of the U.S. Securities and Exchange Commission and stock exchange listing requirements. Prior to attending law school, Cailin worked for a pharmaceutical company.


Represented Midatech Pharma PLC, a publicly traded United Kingdom biopharmaceutical company, in its acquisition of DARA BioSciences, Inc., a U.S. publicly traded company, and its subsequent registration of ordinary shares with the Securities and Exchange Commission and listing on the Nasdaq Capital Market

Represented Hologic, Inc., a Nasdaq-listed developer and manufacturer of medical devices, with the issuances of $1 billion and $350 million in high yield bonds

Assisted a private equity investment fund in its acquisition of several portfolio companies through both stock and asset acquisitions.

Provide ongoing corporate and securities law compliance advice to Nasdaq-listed US companies and foreign private issuers


Boston College Law School - J.D., 2014
Harvard University - B.A., 2009

Bar Admissions